<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NELARABINE</span><br/><span class="topboxtradename">Arranon<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">pyrimidine, antimetabolite</span><br/><b>Prototype: </b>5-Fluorouracil<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg/mL solution in 50 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Nelarabine inhibits DNA synthesis in lymphoblastic T-cells of acute leukemia and lymphoma.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The incorporation of a nelarabine metabolite in the leukemic blast cells halts DNA synthesis and causes cell death. </p>
<h1><a name="uses">Uses</a></h1>
<p> Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe renal impairment; pregnancy (category D); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adult T-Cell Leukemia/Lymphoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span>  1,500 mg/m<sup>2</sup> over 2 h on days 1, 3, and 5, repeated every 21 d<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>  650 mg/m<sup>2</sup> over 1 h for 5 d, repeated every 21 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Standard IV hydration, urine alkalinization, and prophylaxis with allopurinol are advised to manage hyperuricemia in those
            at risk for tumor lysis syndrome.
         </li>
<li>Use gloves and protective clothing to prevent skin contact.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Do not dilute. Transfer the required dose to a PVC or glass container for infusion.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> <i>Adult:</i> Give over 2 h. <i>Child:</i> Give over 1 h.  <img border="0" src="../images/special/bullsm.gif"/> Discontinue IV and notify physician for neurologic adverse events of
                  NCI Common Toxicity Criteria grade 2 or greater.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store vials at 15°30° C (59°86° F). Nelarabine is stable in PVC bags or glass infusion containers
            for 8 h up to 30° C. 
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Abnormal gait, <span class="speceff-common">fatigue,</span>
<span class="speceff-common">pyrexia,</span> rigors. <span class="typehead">CNS:</span>
<span class="speceff-common">Asthenia,</span> ataxia, <span class="speceff-common">dizziness,</span>
<span class="speceff-common">headache, hypoesthesia, neuropathy, paresthesia, somnolence,</span> tremor. <span class="typehead">CV:</span> Chest pain, <span class="speceff-common">edema,</span> hypotension, <span class="speceff-common">petechiae,</span> sinus tachycardia. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">constipation, diarrhea, nausea, vomiting,</span> stomatitis. <span class="typehead">Hematologic/Lymphatic:</span>
<span class="speceff-common">Anemia, neutropenia, thrombocytopenia,</span> increased risk of infection. <span class="typehead">Hepatic:</span> AST levels increased. <span class="typehead">Metabolic:</span> Anorexia, dehydration, hyperglycemia. <span class="typehead">Musculoskeletal:</span> Arthralgia, back pain, muscular weakness, <span class="speceff-common">myalgia,</span> pain in extremities. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Cough, dyspnea, pleural effusion,</span> epistaxis, wheezing. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span>  Metabolism: Bioactivation to ara-GTP, oxidized to uric acid. <span class="typehead">Elimination:</span> Renal. <span class="typehead">Half-Life:</span>  3 h (active metabolite). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report immediately S&amp;S of adverse CNS effects, including altered mental status (e.g., confusion, severe somnolence),
            seizures, and peripheral neuropathy (e.g., numbness, paresthesias, motor weakness, ataxia, paralysis).
         </li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Note: Previous or concurrent treatment with intrathecal chemotherapy or previous craniospinal irradiation may increase risk
            of CNS toxicity.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Report any of the following to a health care provider: seizures; tingling or numbness in hands and feet; problems with fine
            motor coordination; unsteady gait and increased weakness with ambulating; fever or other signs of infections.
         </li>
<li>Use effective contraceptive measures to avoid pregnancy while taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>